Ena Respiratory
ENA Respiratory is a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for the prophylaxis of respiratory viral infections, including COVID-19, rhinovirus and influenza in populations at risk of complications.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | $5.0m | Early VC | |
| Total Funding | 000k | ||
Related Content
ENA Respiratory, headquartered in Melbourne, Australia, is a pioneering biotech company focused on developing innovative treatments for respiratory diseases. The company’s flagship product, INNA 051, is currently in clinical development and aims to address significant unmet needs in respiratory health. ENA Respiratory operates in the healthcare and biotechnology market, specifically targeting respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD).
The company serves a diverse range of clients, including patients suffering from respiratory diseases, healthcare providers, and research institutions. ENA Respiratory’s business model revolves around the research, development, and commercialization of novel respiratory treatments. They generate revenue through partnerships, grants, and contracts, as well as future sales of their proprietary drugs.
ENA Respiratory has formed strategic partnerships to accelerate the development of INNA 051. In 2022, the company joined BLUE, a collaborative initiative between Johnson & Johnson Innovation and the U.S. Biomedical Advanced Research and Development Authority (BARDA). This partnership provides ENA Respiratory with access to a broad network of resources and expertise. Additionally, the company partnered with the U.S.-based COPD Foundation to leverage its global network of accredited centers, scientific expertise, and patient investigators.
In 2023, ENA Respiratory secured a significant contract worth USD 8.18 million from the U.S. Department of Defense to support the ongoing development of INNA 051. This funding underscores the potential impact of their work and the confidence of major institutions in their research.
ENA Respiratory’s team boasts a long history of successful drug development in respiratory diseases, positioning them well to meet the considerable unmet needs in this field. The company has also secured Series A investment to further its research and development efforts.
For more information on INNA 051, visit the [INNA 051 product page](https://enarespiratory.com/inna-051).
Keywords: respiratory diseases, biotech, INNA 051, COPD, clinical development, partnerships, healthcare, innovation, U.S. Department of Defense, Series A investment.